Topical Menthol For Tear Secretion
NCT07109609 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2025-09-16
Summary
Tears are the natural way to keep eyes moist, and tears are important for good vision and healthy eyes. Eyes without enought tears get dry and sore.
The natural and normal way to stimulate secretion of tears is by turning on cold sensors that are located on the cornea of the eye. Tear are normally released across the eyeball in a finely balanced system that balances out that natural evaporation. But sometimes there is not enough tear secretion to balance out the evaporation of tears and eyes can get sore.
The aim here is to test whether menthol in its vapor form may possibly turn on those cold sensors and thus cause secretion of tears. Use of menthol vapors may be like having a switch to release more tears.
The aim of this clinical trial is to test the hypothesis that a menthol solution applied onto a cheek will release enough menthol vapor into the air flowing up over the eye's cornea to stimulate cold sensors enough to make a tear flow from the eye.
If the hypothesis that menthol safely stimulates tear secretion in healthy people proves to be correct, then this clinical trial may inspire more new research into the use of menthol as an alternative to the use of eye drops for some people.
Conditions
- Healthy
- Dry Eyes
Interventions
- DRUG
-
Topical application of 20% menthol solution in MCT oil.
To facilitate reproducible and correct application of the solution, the subject wears glasses while the product is applied. The solution is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers about 12 mg solution, i.e. 2.4 mg menthol to one cheek. Or this method delviers 12 mg of placebo oil. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
- DRUG
-
Topical Placebo Oil rolled onto the cheek.
To facilitate reproducible and correct application of the Placebo oil, the subject wears glasses while the product is applied. The Placebo oil is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers zero active agent. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
Sponsors & Collaborators
-
Stearacl Inc
collaborator INDUSTRY -
Reinhold Vieth
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-08-17
- Primary Completion
- 2025-11-07
- Completion
- 2025-12-01
Countries
- Canada
Study Locations
More Related Trials
-
Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears
NCT02100787 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops
NCT02758327 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study of the TearCare System in Adults With Dry Eye Disease
NCT03006978 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants
NCT05992922 ·Status: TERMINATED ·Phase: PHASE2
-
Topical Steroid Treatment For Dry Eye
NCT02218827 ·Status: UNKNOWN ·Phase: NA
-
A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN)
NCT02014922 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the TearCare System in Dry Eye Disease
NCT03588624 ·Status: COMPLETED ·Phase: NA
-
Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation
NCT01736527 ·Status: COMPLETED ·Phase: PHASE1
-
Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome
NCT02986750 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of NOV03 on the Tear Film
NCT05723770 ·Status: COMPLETED ·Phase: PHASE4
-
Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
NCT03097614 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers
NCT01339936 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease
NCT02260960 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
TearCare System to Treat Dry Eye Disease
NCT03857919 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
NCT03334539 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnostic Evaluation of the Tear Film
NCT00761917 ·Status: COMPLETED
-
LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
NCT02365519 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Effect of MiboFlo in Dry Eye Patients
NCT04310969 ·Status: COMPLETED ·Phase: NA
-
Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease
NCT01753596 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
NCT01960010 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease
NCT00679718 ·Status: COMPLETED ·Phase: PHASE2
-
Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT
NCT02585375 ·Status: UNKNOWN ·Phase: PHASE4
-
An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations
NCT06538662 ·Status: COMPLETED ·Phase: PHASE3
-
Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye
NCT03569202 ·Status: COMPLETED ·Phase: NA
-
Evaluation of FID 114657 in Sjogren's Syndrome Subjects
NCT01079871 ·Status: COMPLETED ·Phase: NA